As our readers know we like to look at the 52 week high list on down days to create a list of stocks to begin our stock selection process but even more important is the 52 week high list during a series of down session coupled with an overall weak month.
With the two day Federal Reserve meeting in the rearview mirror this morning markets are remain flat in the pre-market albeit the DOW and S&P 500 are tilted to the down side.
With so much media focus on shutdown & the debt ceiling crisis in the US, I thought that today I wouldn’t add further to the thousands of words being written and spoken. Instead, I want to tell you a story.
Investors are expecting an eventual reduction of support by the Fed, and Merkel winning the election this weekend. However, what stock markets have not priced in is the resurgence of Eurozone troubles into the headlines. So what are the options, why is this important and how will this effect markets?
London, UK; 18 September 2013: GW Pharmaceuticals plc (GWPH) announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.
This week was always going to be a tricky one for both traders and investors, with the market’s primary focus being the FOMC meeting on Wednesday. The meeting at which the FED is likely to signal the beginning of the end of its bond buying program. Well, that’s the theory anyway, but given the less that stellar NFP data, this is far from certain.
As our readers know we like to look at the 52 week high list on down days to create a list of stocks to begin our stock selection process but even more important is the 52 week high list during a series of down session coupled with an overall weak month.
The Goldman Sachs (GS, quote) Hedge Fund Report was released this morning providing readers a significant amount of hedge fund data including the fund’s top holding based on their 13F filings from the second quarter.
With 90 minutes before the start of a new week of trading in the U.S. markets – futures are pointing to a slightly lower open despite uncertainty whether the U.S. Federal Reserve will being tapering its $85 billion asset buying program.
With the long summer days now coming to an end, it’s time to re-visit that perennial gauge of market risk, the VIX for a view of whether the equity market is indeed over bought, and likely to reverse dramatically.
